Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
AstraZeneca Pharma India Limited (506820) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of AstraZeneca Pharma India Limited ₹810, price ₹6,030, upside -86.6%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
AP
Thin data
Sep 24, 2026
AstraZeneca Pharma India Limited
506820 · BSEStretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹810.13 · Strongly overvalued (−86.6%)
!Quality 57/100
!Mixed Growth (revenue 5y +15.6 %/yr)
!Thin margins · 9.9% net margin (TTM)
✓0.1% dividend yield · Well covered
!Moderate moat 59/100
!Evidence only low, so the estimate is less certain
Watch AstraZeneca Pharma India Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹2,409 – ₹10,442 · fair‑value band ₹478.38 – ₹1,064 · the ₹6,030 price screens above the ₹810.13 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names.
Show more
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names. The company offers products in the areas of cardiovascular, renal, metabolic, oncology, antidiabetic, respiratory, inflammation, and autoimmunity diseases. It also provides clinical trial services. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Stock analysis
AstraZeneca Pharma India Limited (506820) currently trades at ₹6,030, while our model-based Fair Value estimate is ₹810.13, 86.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹1,255 per share, and 0 of the 26 models we run sit above the ₹6,030 price.
Bear case: the Asset-Based group reads lowest at ₹206.45, and 26 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹478.38 (bear) to ₹1,064 (bull), the price of ₹6,030 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
AstraZeneca Pharma India Limited reported revenue of ₹17.2B in FY2025 versus ₹8.1B in FY2021, a compound +20.5%/yr. Reported net income was ₹1.2B in FY2025, compounding +5.5%/yr from FY2021.
Key figures
Market cap ₹151B (≈ $1.6B) · P/E ratio 154.2 · P/S ratio 10.4 · EPS (TTM) ₹32.50 · Dividend yield 0.1% · Net margin 6.7% · Return on equity 22.1% · Return on assets (EBIT) 11.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −87%, 506820 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹206.45 to ₹2,119). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹478.38
Fair Value ₹810.13
Bull ₹1,064
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹28.50 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income
₹290.50
₹349.86
₹474.71
76
FCF DCF
₹328.74
₹516.31
₹992.22
74
Growth DCF
₹313.81
₹549.19
₹942.92
72
All 26 models by family
DCF Models
FCF DCF
₹328.74
₹516.31
₹992.22
74
Owner Earnings
₹780.55
₹1,571
₹3,009
69
5Y Revenue Exit
₹408.38
₹780.77
₹1,450
66
5Y EBITDA Exit
₹537.63
₹1,064
₹1,950
68
5Y P/E Exit
₹602.61
₹1,281
₹2,149
65
10Y Revenue Exit
₹360.85
₹742.96
₹1,258
61
10Y EBITDA Exit
₹457.83
₹960.41
₹1,872
61
10Y P/E Exit
₹499.38
₹1,070
₹2,044
57
Earnings-Based
Graham-Dodd
₹314.81
₹2,119
₹2,970
63
Lynch FV
₹620.92
₹887.03
₹1,153
61
PEG = 1.0
₹620.92
₹887.03
₹1,153
57
EPV
₹253.28
₹286.36
₹313.92
70
Dividend Discount
Gordon GGM
₹186.46
₹336.00
₹462.55
68
DDM Multi-Stage
₹186.46
₹306.93
₹358.93
67
Multiples
P/E Multiple
₹763.88
₹1,019
₹1,273
63
P/S Multiple
₹590.27
₹787.03
₹983.79
58
P/B Multiple
₹590.27
₹787.03
₹983.79
55
EV/EBIT
₹610.28
₹810.13
₹1,010
63
EV/EBITDA
₹672.43
₹893.00
₹1,114
64
EV/Revenue
₹438.64
₹622.04
₹805.43
51
Asset-Based
NCAV (Graham)
₹154.07
₹206.45
₹308.14
51
Growth DCF
Growth DCF
₹313.81
₹549.19
₹942.92
72
Rev-Margin DCF
₹408.38
₹803.45
₹1,385
67
Economic Profit
Residual Income
₹290.50
₹349.86
₹474.71
76
ROIC Compounder
₹253.28
₹286.36
₹321.93
70
Growth Earnings
Growth-Adj P/E
₹878.78
₹1,255
₹1,632
67
Notify me when 506820 reaches fair value
Put 506820 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
57/100
Of which business quality 57 · Market factors (momentum, volatility) 33
Profitability
64
Margins and returns on capital today
Quality Growth
29
Are margins and returns improving?
Cashflow
43
Earnings quality: real cash, not paper profit
Fin. Strength
76
Balance sheet, leverage, solvency risk
Investment
42
Disciplined investing over empire-building
Low Volatility
92
Calm price path (market factor)
Momentum
13
Price trend over the last 3–12 months (market factor)
52W Momentum
0
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+32.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.6%
Start year 2020 (pandemic). Over 10 years: +13.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.9%
Dividend (yield on the price)0.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 7%
Compare AstraZeneca Pharma India Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)Health Care · 2462 stocks
Beats the sector median on 5/12 measures
A mixed picture versus its sector peers.
Valuation Multiplesvs Health Care median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Makers Laboratories Limited 506919 | ₹188.25 | ₹105.20 | −44% |
| COLINZ COLINZ | ₹76.20 | ₹34.72 | −54% |
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| UnitedHealth Group UNH | $367.08 | $295.49 | −20% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Thermo Fisher Scientific Inc TMO | $675.05 | $686.04 | +2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is AstraZeneca Pharma India Limited (506820) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹810.13 versus a price of ₹6,030, about −87% upside (overvalued).
What is the fair value of 506820?
Our model-based fair value for AstraZeneca Pharma India Limited is ₹810.13 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹6,030.
What is the quality score of 506820?
AstraZeneca Pharma India Limited has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AstraZeneca Pharma India Limited (506820)?
Our model-based price target is the fair value of ₹810.13 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹478.38, optimistic scenario ₹1,064. It is a calculation from audited fundamentals, not an analyst target.
What is the AstraZeneca Pharma India Limited stock forecast for 2026?
Our models put fair value at ₹810.13, about −87% upside versus a price of ₹6,030 (overvalued). Cautious scenario ₹478.38, optimistic scenario ₹1,064. The calculation is refreshed regularly with new filings.
What is the revenue of AstraZeneca Pharma India Limited (506820)?
AstraZeneca Pharma India Limited reported trailing-twelve-month revenue of about ₹8.2B (latest available figure, as of Sep 24, 2026).
Does AstraZeneca Pharma India Limited pay a dividend?
AstraZeneca Pharma India Limited currently shows a dividend yield of about 0.07% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of AstraZeneca Pharma India Limited (506820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AstraZeneca Pharma India Limited it is ₹810.13 per share (as of Sep 24, 2026), against a price of ₹6,030. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is AstraZeneca Pharma India Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 506820 trades above its calculated fair value: price ₹6,030, fair value ₹810.13, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 506820?
No. The price is what the market pays today (₹6,030); the fair value is what the company's own numbers justify (₹810.13). For AstraZeneca Pharma India Limited the two are ₹5,220 per share apart. That gap is exactly why we show both numbers side by side.
How much is AstraZeneca Pharma India Limited worth?
The market values AstraZeneca Pharma India Limited at about ₹151B (market capitalisation, as of Sep 24, 2026). Per share that is ₹6,030; our models calculate a fair value of ₹810.13 per share.
What do the bullish and bearish scenarios say about 506820?
Our models span a range for AstraZeneca Pharma India Limited: cautious scenario ₹478.38, base ₹810.13, optimistic ₹1,064 per share (as of Sep 24, 2026, price ₹6,030). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 506820?
AstraZeneca Pharma India Limited trades at a price-to-earnings ratio of 154.2 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹810.13 is built from several models across several years. Other multiples: P/B 14.0, P/S 13.1, EV/EBITDA 95.1.
How solid is the balance sheet of AstraZeneca Pharma India Limited (506820)?
Balance-sheet figures for AstraZeneca Pharma India Limited (as of Sep 24, 2026): return on equity 22.1%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 506820 from its 52-week high?
AstraZeneca Pharma India Limited trades at ₹6,030, about 38% below its 52-week high of ₹9,774 and at the low of ₹6,030 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹810.13 is for.
Which stocks are comparable to AstraZeneca Pharma India Limited?
From the same area (Healthcare) we also value Makers Laboratories Limited, COLINZ, Eli Lilly and Company, Johnson & Johnson,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AstraZeneca Pharma India Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹6,030, calculated fair value ₹810.13 (−87%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 506820 calculated?
We run AstraZeneca Pharma India Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹810.13, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. AstraZeneca Pharma India Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AstraZeneca Pharma India Limited (506820)?
The closing price on Oct 1, 2026 was ₹6,030. Our model-based fair value is ₹810.13, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AstraZeneca Pharma India Limited right now?
The price sits above even our optimistic bull case (₹1,064). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹478.38 to ₹1,064) leaves room in how you read the outcome.
Key figures of AstraZeneca Pharma India Limited
How large is the market capitalisation of AstraZeneca Pharma India Limited (506820)?
The market capitalisation of AstraZeneca Pharma India Limited is ₹151B (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AstraZeneca Pharma India Limited (506820)?
The price-to-sales ratio of AstraZeneca Pharma India Limited is 10.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AstraZeneca Pharma India Limited (506820)?
Earnings per share at AstraZeneca Pharma India Limited are ₹32.50 (price ÷ EPS = P/E 154.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AstraZeneca Pharma India Limited (506820)?
The dividend yield of AstraZeneca Pharma India Limited is 0.1% (payout 12.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AstraZeneca Pharma India Limited (506820)?
The net margin of AstraZeneca Pharma India Limited is 6.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AstraZeneca Pharma India Limited (506820)?
The return on equity (ROE) of AstraZeneca Pharma India Limited is 22.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AstraZeneca Pharma India Limited (506820)?
On an EBIT basis the return on assets of AstraZeneca Pharma India Limited is 11.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AstraZeneca Pharma India Limited (506820)?
The operating margin of AstraZeneca Pharma India Limited is 11.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AstraZeneca Pharma India Limited (506820)?
Revenue at AstraZeneca Pharma India Limited is growing +0.5% versus a year earlier (3y avg +28.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AstraZeneca Pharma India Limited (506820)?
Earnings per share at AstraZeneca Pharma India Limited are growing +82.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch AstraZeneca Pharma India Limited in the live analysis
One click puts AstraZeneca Pharma India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.